Globe News Wire
19 Nov 2026, 08:30 UTC · 10h ago
Asgard Therapeutics awarded €2.5m EIC Accelerator grant to advance lead program AT-108 toward the clinic
Impact · against what's priced in
Asgard Therapeutics receives a non-dilutive €2.5m grant and potential access to €10m in equity, reducing near-term financing risk. This provides a modest capital cushion to push the AT-108 program toward first-in-human trials.
Scored by the NIS engine · methodology.





